



*Press release from Biora AB
(publ), June 4, 2003*

N o 10 / 03

F O R

I M M E D I A T E R E L E A S E

**A new indication for Emdogain[®] Gel
approved in the US**

Biora has received U.S. Food and Drug Administration (FDA) approval for a new indication for EmdogainGel in the treatment of mandibular Class II furcations with minimal proximal bone loss (periodontal defects between the tooth roots in the lower jaw). Biora plans to launch this new indication in the US market in June 2003.

Donna Janson, CEO and President of Biora
comments:

“The recent FDA approval for the use of EmdogainGel in the treatment of furcations defects further demonstrates Emdogain’s regenerative ability and efficacy. Furcation defects are normally challenging to treat, however, the results of a multi-center clinical trial have shown that new tooth supporting tissues can be achieved in these defects following the use of EmdogainGel. The addition of the furcation indication broadens the use of EmdogainGel in the area of periodontal regeneration and strengthens EmdogainGel’s position as the treatment of choice for periodontal defects.”

Emdogain has been approved for treatment of furcation defects in Europe since its introduction in 1996.

Biora develops, manufactures and sells biology-based products for the treatment of dental diseases. The principal product, Emdogain® Gel, which is approved for sale in Europe, North America and Japan naturally regenerates the supporting structure that the tooth has lost due to periodontal disease. Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock Exchange (Stockholmsbörsen) in Sweden.

This press release may contain certain forward- looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward- looking statements and are more fully discussed in periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

- Svante Lundell, CFO and Investor Relations, Biora
tel: +46 70 532 3056
- Donna Janson, President and CEO of Biora, tel:
+46 - 40 - 32 12 28
- <http://www.biora.com>